Aravive Inc (FRA:VE11)
€ 0.0325 0 (0%) Market Cap: 2.72 Mil Enterprise Value: -2.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Aravive Inc Platinum Resistant Ovarian Cancer Transcript

Dec 01, 2020 / NTS GMT
Release Date Price: €4.78 (+2.14%)
Neal Howard
Health Professional Radio - Moderator

Hello, and welcome to Health Professional Radio, I'm your host, Neal Howard. Thank you so much for joining us, again. Going to be speaking this evening with Dr. Gail McIntyre, CEO of Aravive, Inc., and she is joining us here on Health Professional Radio to talk about the urgent need for improved therapeutic approaches to treat patients with ovarian cancer who are resistant to standard care therapy. Welcome to Health Professional Radio, Dr. McIntyre.

Gail McIntyre
Aravive, Inc. - CEO & Board Director

Thank you.

Neal Howard
Health Professional Radio - Moderator

Well, I did, of course, mention that you are CEO of Aravive, Inc. Give us a bit of your background and then talk briefly about Aravive's mission.

Gail McIntyre
Aravive, Inc. - CEO & Board Director

Sure. So my formal training is in biochemistry and biophysics. Actually I'm a Board Certified in toxicology. I spent 30 years in the drug development business,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot